Last reviewed · How we verify
Trivalent inactivated influenza vaccine
Trivalent inactivated influenza vaccine is a Biologic drug developed by Sanofi. It is currently FDA-approved. Also known as: Fluzone®, Vaxigrip, Brand Name: VAXIGRIP, Vaxigrip Junior.
Sanofi's Trivalent inactivated influenza vaccine is a marketed product with a well-established presence in the influenza vaccine market. The key composition patent is set to expire in 2028, providing a period of exclusivity that supports current market positioning. The primary risk is the potential increase in competition following the patent expiry, which could impact revenue and market share.
At a glance
| Generic name | Trivalent inactivated influenza vaccine |
|---|---|
| Also known as | Fluzone®, Vaxigrip, Brand Name: VAXIGRIP, Vaxigrip Junior, Fluzone |
| Sponsor | Sanofi |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Longitudinal Tracking of Bone Marrow Plasma Cell Responses to Licensed Human Vaccines (PHASE4)
- Influenza Vaccination Strategy for Patients With Hematologic Malignancy (PHASE3)
- Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older (PHASE3)
- Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age (PHASE3)
- Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (PHASE3)
- High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater) (PHASE2)
- A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision (EARLY_PHASE1)
- Immunogenicity and Safety of Butantan Quadrivalent Influenza Vaccine (Split Virion, Inactivated) in Infants and Children . (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Trivalent inactivated influenza vaccine CI brief — competitive landscape report
- Trivalent inactivated influenza vaccine updates RSS · CI watch RSS
- Sanofi portfolio CI
Frequently asked questions about Trivalent inactivated influenza vaccine
What is Trivalent inactivated influenza vaccine?
Who makes Trivalent inactivated influenza vaccine?
Is Trivalent inactivated influenza vaccine also known as anything else?
What development phase is Trivalent inactivated influenza vaccine in?
Related
- Manufacturer: Sanofi — full pipeline
- Also known as: Fluzone®, Vaxigrip, Brand Name: VAXIGRIP, Vaxigrip Junior, Fluzone
- Compare: Trivalent inactivated influenza vaccine vs similar drugs
- Pricing: Trivalent inactivated influenza vaccine cost, discount & access